🇺🇸 Repository Corticotropin Injection in United States

2,916 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 423 reports (14.51%)
  2. Malaise — 345 reports (11.83%)
  3. Weight Increased — 343 reports (11.76%)
  4. Drug Ineffective — 298 reports (10.22%)
  5. Dyspnoea — 284 reports (9.74%)
  6. Insomnia — 256 reports (8.78%)
  7. Injection Site Bruising — 254 reports (8.71%)
  8. Headache — 246 reports (8.44%)
  9. Pain — 241 reports (8.26%)
  10. Asthenia — 226 reports (7.75%)

Source database →

Repository Corticotropin Injection in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Repository Corticotropin Injection approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Repository Corticotropin Injection in United States?

Mallinckrodt is the originator. The local marketing authorisation holder may differ — check the official source linked above.